CDK
Cyclin dependent kinase
CDKs (Cyclin-dependent kinases) are serine-threonine kinases first discovered for their role in regulating the cell cycle. They are also involved in regulating transcription, mRNA processing, and the differentiation of nerve cells. CDKs are relatively small proteins, with molecular weights ranging from 34 to 40 kDa, and contain little more than the kinase domain. In fact, yeast cells can proliferate normally when their CDK gene has been replaced with the homologous human gene. By definition, a CDK binds a regulatory protein called a cyclin. Without cyclin, CDK has little kinase activity; only the cyclin-CDK complex is an active kinase.
There are around 20 Cyclin-dependent kinases (CDK1-20) known till date. CDK1, 4 and 5 are involved in cell cycle, and CDK 7, 8, 9 and 11 are associated with transcription.
CDK levels remain relatively constant throughout the cell cycle and most regulation is post-translational. Most knowledge of CDK structure and function is based on CDKs of S. pombe (Cdc2), S. cerevisia (CDC28), and vertebrates (CDC2 and CDK2). The four major mechanisms of CDK regulation are cyclin binding, CAK phosphorylation, regulatory inhibitory phosphorylation, and binding of CDK inhibitory subunits (CKIs).
CDK Isoform Specific Products
-
CDK
(480)
View all products
-
CDK1
(177)
View all products
-
CDK2
(288)
View all products
-
CDK3
(21)
View all products
-
CDK4
(214)
View all products
-
CDK5
(93)
View all products
-
CDK6
(161)
View all products
-
CDK7
(115)
View all products
-
CDK8
(52)
View all products
-
CDK9
(187)
View all products
-
CDK11
(7)
View all products
-
CDK12
(47)
View all products
-
CDK13
(23)
View all products
-
CDK14
(6)
View all products
-
CDK16
(7)
View all products
-
CDK19
(23)
View all products
-
CDC
(21)
View all products
-
CLK
(31)
View all products
-
Pho85
(1)
View all products
-
CDK10
(1)
View all products
-
CDK15
(1)
View all products
-
CDK17
(2)
View all products
-
CDK18
(1)
View all products
-
CDK20
(1)
View all products
-
PITSLRE
(1)
View all products
All Product Categories
-
CDK Inhibitors
(1029)
View all products
-
CDK Agonists
(2)
View all products
-
CDK Antagonists
(2)
View all products
-
CDK Activators
(14)
View all products
-
CDK Modulators
(12)
View all products
-
CDK Degraders
(77)
View all products
-
CDK Controls
(4)
View all products
-
CDK Substrate
(1)
View all products
-
CDK Ligands
(11)
View all products
-
Cyclin-Dependent Kinases (CDKs) Proteins
(81)
View all products
-
Cyclin Dependent Kinase 1 (CDK1) Proteins
(9)
View all products
-
Cyclin-Dependent Kinase 2 (CDK2) Proteins
(11)
View all products
-
Cyclin-Dependent Kinase 3 (CDK3) Proteins
(6)
View all products
-
Cyclin-Dependent Kinase 4 (CDK4) Proteins
(5)
View all products
-
Cyclin-Dependent Kinase 5 (CDK5) Proteins
(5)
View all products
-
Cyclin-Dependent Kinase 6 (CDK6) Proteins
(6)
View all products
-
Cyclin-Dependent Kinase 7 (CDK7) Proteins
(4)
View all products
-
CDK Related Products (1263)
-
Recombinant Proteins (82)
-
Antibodies (42)
-
CDK Isoform Comparison
-
CDK9-IN-33
0 ImagesCat. No.: HY-162619CDK9-IN-33 (compound C35) is a potent, selective and orally active CDK9 inhibitor with IC50 values of 17.44, 160, 316.30, 1771.00, >10000 nM for CDK9, CDK7, CDK2, CDK4, CDK6 respectively. CDK9-IN-33 induces apoptosis. CDK9-IN-33 decreases the protein expression of RPB1 CTD Ser2, RPB1, MCL1. CDK9-IN-33 shows anti-tumor activity. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
RO5068760
0 ImagesCat. No.: HY-111033CAS No.: 947182-25-4RO5068760 is a potent, orally active and selective non-ATP-competitive MEK1/2 inhibitor with an IC50 of 0.025 μM for MEK1. RO5068760 significantly inhibits MAPK pathway activity, thereby inducing G1 cell cycle arrest and apoptosis to inhibit cancer cell growth. RO5068760 exhibits significant efficacy in a broad spectrum of tumors with aberrant MAPK pathway activation. RO5068760 can be used for melanoma, colorectal cancer, non-small cell lung cancer (NSCLC), and pancreatic cancer research. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
CDK9/HDAC1/HDAC3-IN-1
0 ImagesCat. No.: HY-172891CAS No.: 2197029-81-3CDK9/HDAC1/HDAC3-IN-1 is dual-functional inhibitor of CDK9 and HDAC. CDK9/HDAC1/HDAC3-IN-1 inhibits the protein activity of CDK9/HDAC/HDAC3 with IC50 s of 0.17 μM, 1.73 μM and 1.11 μM for CDK9, HDAC1, and HDAC3, respectively. CDK9/HDAC1/HDAC3-IN-1 inhibits cancer cells by inducing cell apoptosis and cell cycle arrest in the G2/M phase, as well as tumor growth in a murine TNBC MDA-MB-231 xenograft model. CDK9/HDAC1/HDAC3-IN-1 has a broad-spectrum anti-cancer activity, such as breast cancer, cervical cancer, and liver cancer. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
CDK-IN-11
0 ImagesCat. No.: HY-149173CAS No.: 2376876-87-6CDK-IN-11 is a heterocyclic compound that has an action of promoting cardiomyocyte maturation. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
CDK5-IN-2
0 ImagesCat. No.: HY-145693CAS No.: 2639542-22-4CDK5-IN-2 (compound 15) is a highly selective CDK5 inhibitor with IC50s of 0.2 and 23 for CDK5/p25 and CDK2/CycA, respectively. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
GSK3-IN-10
0 ImagesCat. No.: HY-172198CAS No.: 844441-56-1GSK3-IN-10 (Compound 4) is a multi-target inhibitor, that mainly targets GSK3α and GSK3β with IC50 of 1.0 nM and 2.0 nM. GSK3-IN-10 inhibits the activation of β-catenin, promotes the neuronal survival, and exhibits a protective effect against endoplasmic reticulum stress. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Cdc7-IN-14
0 ImagesCat. No.: HY-143389CAS No.: 2764866-21-7Cdc7-IN-14 (compound 82) is a potent CDC7 inhibitor with an IC50 of <1 nM. Cdc7-IN-14 has the potential for the research of cancer. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
CDK2-IN-9
0 ImagesCat. No.: HY-144811CAS No.: 2919216-33-2 -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
CDK2 degrader 8
0 ImagesCat. No.: HY-178007CAS No.: 3099145-52-2CDK2 degrader 8 (Compound1) is a CDK2 degrader. CDK2 degrader 8 shows potential anti-tumor activity by targeting CDK2. CDK2 degrader 8 can be used for the study of solid tumors (breast cancer, triple negative breast cancer, ovarian serous cystadenocarcinoma) and liquid tumors (diffuse large B-cell lymphoma, acute myelogenous leukemia) associated with abnormal CDK2 function. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
CDK9-IN-50
0 ImagesCat. No.: HY-183710CAS No.: 3114520-65-6CDK9-IN-50 is a selective and orally active CDK9 inhibitor with an IC50 of 2.2 nM. CDK9-IN-50 targets a distinct CDK9-specific subpocket to disrupt RNA polymerase II Ser2 phosphorylation and downregulate short-lived oncoproteins, including AR-V7 and Myc. CDK9-IN-50 exhibits antiproliferative activity against cancer cells, induces apoptosis and induces tumor growth inhibition in CRPC orthotopic mice models. CDK9-IN-50 can be used for the research of cancer, such as prostate cancer. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Cdc7-IN-13
0 ImagesCat. No.: HY-143387CAS No.: 2764866-23-9Cdc7-IN-13 (compound 84) is a potent CDC7 inhibitor with an IC50 of <1 nM. Cdc7-IN-13 has the potential for the research of cancer. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Cdk13 Rat Pre-designed siRNA Set A
0 ImagesCat. No.: HY-RS02361 -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
TrkA Inhibitor
0 ImagesCat. No.: HY-112471CAS No.: 388626-12-8TrkA Inhibitor (Compound 18) is a CDK2 inhibitor with an IC50 of 0.69 μM over CDK1. TrkA Inhibitor can be used for chemotherapy-induced alopecia research. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
CDK2-IN-13-d3
0 ImagesCat. No.: HY-W478102SCDK2-IN-13-d3 is the deuterium labeled CDK2-IN-13 (HY-W478102). CDK2-IN-13 (Compound 15) is a CDK2 inhibitor with an IC50 of 12 μM. CDK2-IN-13 can be used in research of cancer. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Cdk4 Mouse Pre-designed siRNA Set A
0 ImagesCat. No.: HY-RS02382 -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
CDK11-IN-1 hydrochloride
0 ImagesCat. No.: HY-182764ACDK11-IN-1 hydrochloride is a potent, highly selective, and orally active CDK11 inhibitor with an IC50 of 4 nM, showing 32.5-fold and 2700-fold selectivity over CDK7 and CDK9, respectively. CDK11-IN-1 hydrochloride binds competitively to the ATP-binding pocket of CDK11 and forms a hydrogen bond with the hinge region residue Val163. It inhibits tumor cell proliferation and exhibits antitumor activity in lung cancer xenograft models. CDK11-IN-1 hydrochloride can be used for studies on the pathophysiology of CDK11-mediated tumors, as well as research on malignant tumors such as lung cancer. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Maleimide-PEG8-Val-Ala-PAB-SNS032
0 ImagesCat. No.: HY-161780Maleimide-Val-Ala-PAB-SNS032 is a conjugate of ADC toxin and linker. SNS032 is an inhibitor for CDK, inhibiting the cell cycle at G1/S phase and cell viability of cancer cells. Maleimide-Val-Ala-PAB is a cleavable ADC linker. Maleimide-Val-Ala-PAB-SNS032 can be utilized for the synthesis of ADC molecules. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
CDK9-IN-19
0 ImagesCat. No.: HY-150562CAS No.: 2479306-60-8CDK9-IN-19 is a highly potent and selective CDK9 inhibitor with an IC50 value of 2.0 nM. CDK9-IN-19 has excellent cellular antiproliferative activity, moderate pharmacokinetic property and low hERG inhibition. CDK9-IN-19 significantly induces tumour growth inhibition in an MV4-11 xenograft mice model. CDK9-IN-19 can be used for researching acute myeloid leukaemia (AML). -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
- CLK1-IN-5
-
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
CDK2 degrader 9
0 ImagesCat. No.: HY-181620CDK2 degrader 9 (compound 1) is a CDK2-targeting Molecular Glue with selectivity for GSPT1 and CDK1. CDK2 degrader 9 promotes the ubiquitination and degradation of CDK2 via the ubiquitin ligase pathway. CDK2 degrader 9 is applicable to research related to cancer, solid tumors and hematologic malignancies. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
No matching results
No matching results
No matching results
No matching results
-
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
No matching results
No matching results
No matching results
No matching results
No matching results
No matching results
No matching results
No matching results
No matching results
No matching results
Your Search Returned No Results.
Sorry. There is currently no product that acts on isoform Bcl-2, Bcl-W and Bim together.Please
try each isoform separately.